Clorox Stock Holds Range As CEO Plans Exit, New Wipes Launch

Clorox Company (The) stocks have been trading up by 4.93 percent after strong earnings and upbeat forward guidance boosted sentiment.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CLX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Leadership at CLX is shifting as Linda Rendle plans to step down as CEO for health reasons, while staying on through the search and then in an advisory role.
The board has created an independent committee and hired an external firm to run a structured CEO search, aiming for a smooth, low-drama succession at CLX.
CFRA kept its Hold on CLX but cut the 12‑month price target to $112 from $121 after a mixed Q3 with flat sales, margin pressure, and Lifestyle segment weakness.
Clorox Healthcare is rolling out two new professional disinfecting wipe platforms, with commercial launch expected later this year pending regulatory approvals.
Brand arm Glad is pushing Oscar the Grouch–themed trash bags across Walmart, Target, and Dollar General, adding marketing juice but not a major earnings driver for CLX.

Live Update At 16:01:54 EDT: On Friday, June 05, 2026 Clorox Company (The) stock [NYSE: CLX] is trending up by 4.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CLX has been grinding rather than exploding. Over the last couple of weeks, Clorox Company (The) has mostly traded in the low‑to‑mid $90s, with a recent push from around $88–$90 up toward $94. That’s a decent bounce, but not a breakout. For short‑term traders, CLX is acting like a range name, not a momentum flyer.

Intraday, the latest session shows a steady climb from about $91 at the open to a close near $94.14. The five‑minute chart is a slow staircase higher, not a parabolic spike. That usually means more “drift” than “squeeze” – good for disciplined day trading, tougher for lotto‑ticket chasers.

Fundamentally, CLX is a mature consumer staples story. Trailing revenue sits around $7.1B, but three‑ and five‑year revenue growth are slightly negative. The company is squeezing decent profitability out of a flat top line: EBIT margin around 16.1% and gross margin near 43.9%. The PE ratio near 15.7 and price‑to‑sales around 1.7 put CLX in a moderate valuation zone, not “deep value” and not “hype stock.”

More Breaking News

Leverage is something traders should respect. Long‑term debt is about $2.81B, commercial paper roughly $1.59B, and the current ratio at 0.8 signals tight liquidity. Working capital is negative and book value per share is slightly negative, reflecting heavy treasury stock and leverage. On the flip side, a dividend rate of $4.96 (roughly a 5.5% yield at recent prices) helps anchor longer‑term money, which can dampen volatility for CLX.

Why Traders Are Watching CLX Right Now

The real story around CLX is not a wild price spike; it’s a cluster of fundamental and governance catalysts that traders need to track. At the center is leadership. Clorox announced that Chair and CEO Linda Rendle will step down for health reasons once a new CEO is found. She will stay on as Chair and CEO through the search and then move into an advisory role to support performance and a smooth handoff.

For a consumer staples giant like CLX, CEO changes usually don’t trigger meme‑level fireworks, but they do create headline risk. Some funds simply do not like uncertainty at the top. That can cap upside in the near term, especially while the board’s independent committee and external search firm work through candidates.

At the same time, CFRA reiterated a Hold on CLX and cut its 12‑month price target to $112 from $121 after a mixed Q3. Sales were flat, margins compressed, and the Lifestyle segment showed weakness amid softer demand and ongoing restructuring. Yes, earnings per share beat expectations, but the quality of that beat matters. When an analyst trims FY26–27 EPS estimates, it tells traders that earnings growth may slow, and that usually weighs on re‑rating potential.

Yet CLX is not standing still. Through Clorox Healthcare, the company announced two new professional‑grade disinfecting wipe platforms: Quat Alcohol Disinfecting Wipes and bleach‑free HyperOxi sporicidal wipes. These are aimed at tightening infection‑prevention compliance in healthcare settings, with launch later this year pending approvals. This is not an instant chart mover, but it’s an important medium‑term growth angle that keeps the CLX story from looking stale.

On the lighter side, Glad’s Oscar the Grouch–themed trash bags, rolling through Walmart, Target, and Dollar General, show the CLX brand machine still knows how to grab shelf attention. It’s marketing color, not a core earnings engine, but campaigns like this support pricing power. Add in the upcoming CEO/CFO fireside chat at the dbAccess Global Consumer Conference in Paris, and traders have a clear calendar of touchpoints where new clues on margins, demand trends, and CEO succession timing may drop.

Conclusion

CLX sits at a classic crossroads that experienced traders recognize: solid brand power and cash generation on one side, and leadership overhang plus sluggish growth on the other. The stock’s recent action — grinding higher from the high‑$80s to mid‑$90s — tells you the market is cautious but not panicking about the Linda Rendle transition. The structured CEO search, advisory role, and independent committee all aim to keep CLX out of the “management crisis” bucket.

Fundamentals back that up. CLX is printing healthy profit margins and strong returns on capital, even as three‑ and five‑year revenue growth run slightly negative and Q3 showed margin compression. Debt and a tight current ratio inject risk if operating trends slip, so traders should keep a close eye on future cash‑flow prints and any hints from the upcoming conference appearance.

Meanwhile, the new Clorox Healthcare wipe platforms are a reminder that CLX still has levers to pull in higher‑value, professional markets. If those launches ramp well, they can offset some of the softness in the Lifestyle segment that CFRA flagged when it cut its target to $112. For active traders, CLX looks more like a steady, news‑driven swing candidate than a high‑beta momentum vehicle.

This content is for educational and research purposes only. Or as Tim Sykes likes to say, “This is education, not a trade alert — study the pattern, study the catalysts, and only pull the trigger when your plan and the price action line up.” And in that same spirit of trading discipline, remember what helps many short‑term and swing traders stay prepared: As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.”.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!